Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Eur Urol Oncol. 2022 Jan 2;5(2):216–224. doi: 10.1016/j.euo.2021.12.001

Table 3 –

Questionnaire responses at baseline and 3 mo

Mean baseline ± Std. Dev. (N = 16) Mean 3 mo ± Std. Dev. (N = 16) Mean difference
(95% CI)
P value
FACT-G 82.2 ± 17.8 82.8 ± 17.5 0.6 (−5.2, 6.3) 0.84
 PWB 21.0 ± 6.8 21.6 ± 6.2 0.6 (−1.6, 2.7) 0.59
 SWB 22.9 ± 4.5 23.9 ± 5.3 1.1 (−0.5, 2.7) 0.18
 EWB 18.1 ± 4.0 17.8 ± 5.2 −0.4 (−2.2, 1.5) 0.67
 FWB 20.1 ± 7.1 19.4 ± 7.0 −0.7 (−3.1, 1.7) 0.56
FKSI 44.4 ± 10.6 46.2 ± 9.1 1.8 (−1.6, 5.1) 0.28
EQ-5D-5L Health scale 68.9 ± 22.2 73.9 ± 11.9 5.0 (−5.9, 15.9) 0.34

EQ-5D-5L = EuroQol Group’s five-level; EWB = emotional well-being; FACT-G = Functional Assessment of Cancer Therapy—General; FKSI = Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index; FWB = functional well-being; PWB = physical well-being; sWb = social well-being.